Transforming lives by accelerating innovation in cardiometabolic health
Verdiva Bio is a clinical-stage biopharmaceutical company developing next-generation oral and injectable therapies for obesity and cardiometabolic disorders. Its lead asset VRB-101 is an oral, once-weekly GLP-1 peptide analog advancing through Phase 2 clinical trials, with additional pipeline programs including amylin agonists and combination therapies. The company launched in January 2025 with $411M in Series A financing and applies emerging gut-brain biology science to deliver more patient-friendly treatment options.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountJan 2025
Create a free account to see which investors have funded this company.
Create Free Account
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Develops Gene Writing technology and non-viral delivery to create in vivo genetic medicines for m...
Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...
San Diego-based clinical stage biopharmaceutical company focused on the development of small mole...
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
